Telix Pharmaceuticals (TLX) Other Non-Current Assets (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Other Non-Current Assets for 3 consecutive years, with $28.8 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 79.31% to $28.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.8 million through Dec 2025, up 79.31% year-over-year, with the annual reading at $28.8 million for FY2025, 91.0% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $28.8 million at Telix Pharmaceuticals, up from $16.1 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $28.8 million in Q4 2025, with the low at $381480.4 in Q4 2023.
  • Average Other Non-Current Assets over 3 years is $15.1 million, with a median of $16.1 million recorded in 2024.
  • The sharpest move saw Other Non-Current Assets skyrocketed 4113.99% in 2024, then skyrocketed 79.31% in 2025.
  • Over 3 years, Other Non-Current Assets stood at $381480.4 in 2023, then surged by 4113.99% to $16.1 million in 2024, then surged by 79.31% to $28.8 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $28.8 million, $16.1 million, and $381480.4 for Q4 2025, Q4 2024, and Q4 2023 respectively.